US Broker Ratings

SIGA Technologies Inc. (SIGA) Stock Analysis: Unpacking the Forward P/E of 4.08 in a Volatile Healthcare Market

SIGA Technologies Inc. (NASDAQ: SIGA), a leading player in the health security market with a focus on antiviral treatments, presents a unique proposition for investors, particularly given its remarkably low..

iRadimed Corporation (IRMD) Stock Analysis: Exploring a 19% Upside Potential in the Healthcare Sector

iRadimed Corporation (NASDAQ: IRMD), a leading player in the healthcare sector, has been making waves with its innovative medical devices that cater specifically to the magnetic resonance imaging (MRI) market...

Immunome, Inc. (IMNM)

⚠️ No article content returned.

..

Tectonic Therapeutic, Inc. (TECX): Investor Outlook with a Staggering 279% Potential Upside

Tectonic Therapeutic, Inc. (NASDAQ: TECX), a promising player in the biotechnology sector, is capturing attention with a potential upside of 279.07%, according to analysts. Specializing in the discovery and development..

Septerna, Inc. (SEPN) Stock Analysis: Exploring the 107.62% Potential Upside in Biotechnology

Septerna, Inc. (NASDAQ: SEPN), a promising player in the biotechnology sector, stands at the intersection of innovation and opportunity, with a striking potential upside of 107.62% according to analyst estimates...

Castle Biosciences, Inc. (CSTL) Investor Outlook: Analyzing a Potential 80.89% Upside

Castle Biosciences, Inc. (NASDAQ: CSTL) emerges as a compelling opportunity within the healthcare sector, specifically in the diagnostics and research industry. Headquartered in Friendswood, Texas, this molecular diagnostics company focuses..

Semler Scientific, Inc. (SMLR) Stock Analysis: Navigating Revenue Challenges with Strong Cash Flow

Semler Scientific, Inc. (NASDAQ: SMLR), a notable player in the healthcare sector specializing in medical devices, is currently facing a complex financial landscape. Headquartered in Santa Clara, California, the company’s..

Xeris Biopharma Holdings (XERS): Investor Outlook Amid Strong Revenue Growth and Promising Analyst Ratings

Xeris Biopharma Holdings, Inc. (XERS) is a company that is capturing the attention of investors within the biotechnology sector due to its impressive revenue growth and favorable analyst ratings. Headquartered..

Fortrea Holdings Inc. (FTRE) Stock Analysis: Exploring a 29.81% Potential Upside in the Biotech Sector

Fortrea Holdings Inc. (NASDAQ: FTRE) presents a compelling opportunity for investors intrigued by the biotechnology sector. As a contract research organization, Fortrea offers a comprehensive suite of biopharmaceutical product and..

Immatics N.V. (IMTX): Investor Outlook with a Potential 138.89% Upside

Immatics N.V. (NASDAQ: IMTX) is gaining attention in the healthcare sector with its innovative approach to cancer treatment through T cell redirecting immunotherapies. This biotechnology company, headquartered in Tübingen, Germany,..

Arvinas, Inc. (ARVN) Stock Analysis: A Potential 145% Upside in the Biotech Sector

For investors seeking opportunities in the healthcare sector, particularly in biotechnology, Arvinas, Inc. (NASDAQ: ARVN) presents an intriguing prospect. This clinical-stage company is pioneering in the field of targeted protein..

Vir Biotechnology (VIR) Stock Analysis: Potential 201% Upside Amid Analyst Optimism

Investors with a keen eye on the biotechnology sector may want to consider the intriguing case of Vir Biotechnology, Inc. (VIR), a company that has recently caught attention due to..

Claritev Corporation (CTEV) Stock Analysis: Navigating a Healthcare Data Giant with a 67.53 RSI

Claritev Corporation (CTEV), a notable player in the healthcare sector, operates at the intersection of data analytics and technology-enabled cost management. Specializing in health information services, the company is making..

LENZ Therapeutics, Inc. (LENZ) Stock Analysis: Analyst Ratings Point to Significant 29.89% Upside

Investors with a keen eye on the biotechnology sector may find LENZ Therapeutics, Inc. (NASDAQ: LENZ) an intriguing opportunity. As a biopharmaceutical company dedicated to the development and commercialization of..

Cogent Biosciences (COGT) Stock Analysis: Exploring a 49% Potential Upside in the Biotech Sector

Cogent Biosciences, Inc. (NASDAQ: COGT) is gaining traction among investors with a compelling narrative in the biotechnology sector. With a market capitalization of $1.58 billion, this Waltham, Massachusetts-based company is..

Pharvaris N.V. (PHVS) Stock Analysis: A Biotech with 72.83% Potential Upside and Strong Buy Ratings

Pharvaris N.V. (NASDAQ: PHVS), a dynamic player in the biotechnology sector, is making notable waves in the healthcare industry. This Swiss-based company, specializing in the development of therapies for rare..

Bicara Therapeutics Inc. (BCAX) Investor Outlook: Exploring a Potential 228% Upside in the Biotechnology Sector

Bicara Therapeutics Inc. (NASDAQ: BCAX) has captured the attention of investors with a reported potential upside of 228.63%, making it a compelling prospect in the competitive field of biotechnology. With..

Anavex Life Sciences Corp. (AVXL) Stock Report: Potential 207% Upside Sparks Investor Interest

Anavex Life Sciences Corp. (NASDAQ: AVXL), a clinical-stage biopharmaceutical company, is capturing investor attention with its promising portfolio of therapeutic candidates targeting central nervous system diseases. Despite its current market..

InnovAge Holding Corp. (INNV) Stock Analysis: Analyzing the 19% Potential Upside Amid Healthcare Expansion

InnovAge Holding Corp. (NASDAQ: INNV), a key player in the healthcare sector, is capturing the attention of investors with its distinct approach to senior care and an intriguing potential upside..

Tilray Brands, Inc. (TLRY) Stock Analysis: Unpacking the 107% Potential Upside Amidst Market Volatility

Tilray Brands, Inc. (NASDAQ: TLRY) stands at the crossroads of opportunity and risk within the healthcare sector, specifically in the specialty and generic drug manufacturing industry. Based in Canada, this..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds